A Randomized Phase 2 Trial of Cediranib and
Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma who have not received Prior VEGF Therapy
Not exact matches
In tumors formed by human breast cancer cells, DNA damage (brown staining) is increased by simultaneous
Olaparib treatment and PGAM1 suppression (right) when
compared to either
Olaparib treatment (left) or PGAM1 suppression (center) alone.
The trial
compared the activity of the combination of the drug
olaparib, which blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs.
olaparib alone.
Tumours shrank in about 60 % of women who received the targeted drug, called
olaparib (Lynparza),
compared with 29 % of those who received chemotherapy.
The researchers found that women who took
olaparib had a median of 8.4 months before their cancer came back,
compared to 4.8 months for those on the placebo.